News

Public · Published

Weekly Recap: Q3 beat estimates and growth drugs drove sales growth

Amgen reported third-quarter revenue of $10.37 billion, up 8%, and adjusted earnings per share of $6.45, up 14%; both exceeded estimates. Six key growth drugs rose 27% year over year and contributed over 70% of product sales. Amgen also raised its 2026 revenue and earnings forecasts.

Published:

Updated:

What happened

Amgen reported third-quarter revenue of $10.37 billion, up 8%, and adjusted earnings per share of $6.45, up 14%; both exceeded estimates. Six key growth drugs rose 27% year over year and contributed over 70% of product sales. Amgen also raised its 2026 revenue and earnings forecasts.

Confirmed

Global impact / market context

The results link Amgen’s growth to a concentrated group of medicines: stronger sales can lift revenue, while successful trials may support future sales if treatments gain approval and reach patients. Raised forecasts indicate management expects stronger performance, but the supplied article gives no revised figures.

Analyst inference

The article presents a mix of current sales growth, trial results and planned research, rather than confirmed commercial launches from the newer studies. Investors therefore have evidence of stronger quarterly performance, but future revenue depends on trial progress, regulatory decisions and adoption.

Analyst inference

What to watch

  1. Track whether Amgen’s six key growth drugs continue growing and maintain their share of product sales, since changes could affect the company’s reported revenue. Analyst inference
  2. Watch for further trial updates on IMDELLTRA combinations, TEZSPIRE and dazodalibep; the article reports positive results but provides no approval or launch announcement. Confirmed
  3. Check for details of Amgen’s raised 2026 revenue and earnings forecasts, including revised figures, which would clarify the expected scale of growth. Analyst inference

Evidence

  • Original source link unavailable